Infection with <i><scp>H</scp>elicobacter bilis</i> but not <i><scp>H</scp>elicobacter hepaticus</i> was Associated with Extrahepatic Cholangiocarcinoma

Segura-López, F.; Avilés-Jiménez, Francisco; Güitrón-Cantú, Alfredo; Valdez-Salazar, Hilda Alicia; León-Carballo, Samuel; Guerrero-Pérez, Leoncio; Fox, James G.; Torres, Javier

doi:10.1111/hel.12195

Cited by 33 publications

(24 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cholangiocarcinoma (CCA) is a malignant tumor arising from biliary epithelial cells, and is the sixth leading cause of gastrointestinal cancer in the West and presents a high incidence rate in East Asia [1, 2]. Furthermore, CCA mortality rates have increased worldwide over several decades.…”

Section: Introductionmentioning

confidence: 99%

ZHX1 Promotes the Proliferation, Migration and Invasion of Cholangiocarcinoma Cells

et al. 2016

View full text Add to dashboard Cite

Zinc-fingers and homeoboxes 1 (ZHX1) is a transcription repressor that has been associated with the progressions of hepatocellular carcinoma, gastric cancer, and breast cancer. However, the functional roles of ZHX1 in cholangiocarcinoma (CCA) have not been determined. We investigated the expression and roles of ZHX1 during the proliferation, migration, and invasion of CCA cells. In silico analysis and immunohistochemical studies showed amplification and overexpression of ZHX1 in CCA tissues. Furthermore, ZHX1 knockdown using specific siRNAs decreased CCA cell proliferation, migration, and invasion, whereas ZHX1 overexpression promoted all three characteristics. In addition, results suggested EGR1 might partially mediate the effect of ZHX1 on the proliferation of CCA cells. Taken together, these results show ZHX1 promotes CCA cell proliferation, migration, and invasion, and present ZHX1 as a potential target for the treatment of CCA.

show abstract

Section: Introductionmentioning

confidence: 99%

ZHX1 Promotes the Proliferation, Migration and Invasion of Cholangiocarcinoma Cells

et al. 2016

View full text Add to dashboard Cite

show abstract

“…The Helicobacter species, H. bilis, in the human bile duct cancer cell line, HuCCT-1, activated NF-jB activity independent of the tumor stage. This was associated with production of vascular endothelial growth factor (VEGF) [176] and was later shown in extrahepatic cholangiocellular carcinoma (CCC) specimens to occur especially within the common bile duct [177].…”

Section: Bacteriamentioning

confidence: 94%

NF-κB signaling and crosstalk during carcinogenesis

Brücher

Läng

Jamall

2019

4open

View full text Add to dashboard Cite

Transcription factors (TFs) are proteins that control the transcription of genetic information from DNA to mRNA by binding to specific DNA sequences either on their own or with other proteins as a complex. TFs thus support or suppress the recruitment of the corresponding RNA polymerase. In general, TFs are classified by structure or function. The TF, Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), is expressed in all cell types and tissues. NF-κB signaling and crosstalk are involved in several steps of carcinogenesis including in sequences involving pathogenic stimulus, chronic inflammation, fibrosis, establishment of its remodeling to the precancerous niche (PCN) and transition of a normal cell to a cancer cell. Triggered by various inflammatory cytokines, NF-κB is activated along with other TFs with subsequent stimulation of cell proliferation and inhibition of apoptosis. The involvement of NF-κB in carcinogenesis provides an opportunity to develop anti-NF-κB therapies. The complexity of these interactions requires that we elucidate those aspects of NF-κB interactions that play a role in carcinogenesis, the sequence of events leading to cancer.

show abstract

“…A lot of risk factors including primary sclerosing cholangitis, bile duct abnormalities, infection, metabolic disorders and genetic susceptibility have been reported to be associated with ECCA, but no specific predisposing factors have been identified up to now . ECCA is a relatively uncommon but highly malignant cancer with the incidence of 0.82/100 000 in the United States . At present, complete resection remains the most effective and only potentially curative treatment for ECCA, but most patients present with advanced unresectable disease mainly due to the lack of reliable serum biomarkers .…”

Section: Introductionmentioning

confidence: 99%

“…In spite of multiple studies on novel molecules for diagnosis in ECCA, the progress in clinical translation has so far been limited. The overall prognosis of ECCA patients is reportedly dismal with the median survival less than 24 months and once diagnosed, few cases could survive for more than 5 years . Thus, more precise markers with high sensitivity and specificity for ECCA are in urgent need which will benefit the patients and expedite the discovery of novel therapeutic strategies.…”

Section: Introductionmentioning

confidence: 99%

Serum N‐glycans outperform CA19‐9 in diagnosis of extrahepatic cholangiocarcinoma

et al. 2017

View full text Add to dashboard Cite

Extensive efforts have been devoted to improve the diagnosis of extrahepatic cholangiocarcinoma (ECCA) due to its silent clinical character and lack of effective diagnostic biomarkers. Specific alterations in N-glycosylation of glycoproteins are considered a key component in cancer progression, which can serve as a distinct molecular signature for cancer detection. This study aims to find potential serum N-glycan markers for ECCA. In total, 255 serum samples from patients with ECCA (n = 106), benign bile tract disease (BBD, n = 60) and healthy controls (HC, n = 89) were recruited. Only 2 μL of serum from individual patients was used in this assay where the N-glycome of serum glycoproteins was profiled by DNA sequencer-assisted fluorophore-assisted capillary electrophoresis (DSA-FACE) technology. Multi-parameter models were constructed by combining the N-glycans and carbohydrate antigen 19-9 (CA19-9) which is currently used clinically. Quantitative analyses showed that among 13 N-glycan structures, the bifucosylated triantennary N-glycan (peak10, NA3F2) presented the best diagnostic performance for distinguishing ECCA from BBD and HC. Two diagnostic models (Glycotest1 and Glycotest2) performed better than single N-glycan or CA19-9. Additionally, two N-glycan structures (peak9, NA3Fb; peak12, NA4Fb) were tightly related to lymph node metastasis in ECCA patients. In conclusion, sera of ECCA showed relatively specific N-glycome profiling patterns. Serum N-glycan markers and models are novel, valuable and noninvasive alternatives in ECCA diagnosis and progression monitoring.

show abstract

Infection with Helicobacter bilis but not Helicobacter hepaticus was Associated with Extrahepatic Cholangiocarcinoma

Abstract: In conclusion, infection with H. bilis but neither H. Hepaticus nor S. typhi was significantly associated with ECCA, particularly with tumors located in the common bile duct.

Cited by 33 publications

References 51 publications

ZHX1 Promotes the Proliferation, Migration and Invasion of Cholangiocarcinoma Cells

ZHX1 Promotes the Proliferation, Migration and Invasion of Cholangiocarcinoma Cells

NF-κB signaling and crosstalk during carcinogenesis

Serum N‐glycans outperform CA19‐9 in diagnosis of extrahepatic cholangiocarcinoma

Contact Info

Product

Resources

About